A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
Completed · Phase 1/Phase 2
Conditions studied: Prostate Cancer
In brief
A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same doses of abiraterone and steroids they were receiving prior to study entry and will be randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with abiraterone. Once the best regimen is established in Part A, based on safety and antitumor activity, patients will be randomized to the selected treatment regimen and dose of AT13387 in combination with abiraterone or AT13387 alone in Part B (Phase 2).
Key facts
- Study ID
- NCT01685268
- Run by
- Astex Pharmaceuticals, Inc.
- People needed
- 49
- Starts
- 2012-09-01
- Expected to finish
- 2014-12-01
- Last updated by the study team
- 2024-08-02
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- University of California, Los Angeles Institute of Urologic Oncology — Los Angeles, California, United States
- Stanford Cancer Center — Stanford, California, United States
- Holy Cross Hospital — Fort Lauderdale, Florida, United States
- Florida Cancer Specialists-Fort Myers — Fort Myers, Florida, United States
- Lakeland Regional Cancer Center — Lakeland, Florida, United States
- Southern Illinois University School of Medicine — Springfield, Illinois, United States
- University of Maryland, Greenebaum Cancer Center — Baltimore, Maryland, United States
- Center for Cancer & Blood Disorders — Bethesda, Maryland, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- University of Nebraska Medical Center — Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Clinical Research Alliance, Inc. — Lake Success, New York, United States
- Columbia University Medical Center — New York, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- SUNY Upstate Medical University — Syracuse, New York, United States
- Cleveland Clinic — Cleveland, Ohio, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- The West Clinic — Memphis, Tennessee, United States
- Northwest Medical Specialists, PLLC — Tacoma, Washington, United States
- Centre hospitalier de l'Universite de Montreal (CHUM) — Montreal, Quebec, Canada
- Centro Integral Oncologico Clara Campal — Madrid, Spain
- Brighton & Sussex University Hospitals NHS Trust — Brighton, United Kingdom
- Cambridge University Hospitals NHS Foundation Trust — Cambridge, United Kingdom
- Velindre Cancer Center — Cardiff, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.